Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Maintenance therapy with low-dose decitabine and venetoclax after allogeneic stem cell transplantation for patients with acute leukemia/myelodysplastic syndrome: a non-randomised, open-label, phase II study

Next Previous
Search
Trial Profile

Maintenance therapy with low-dose decitabine and venetoclax after allogeneic stem cell transplantation for patients with acute leukemia/myelodysplastic syndrome: a non-randomised, open-label, phase II study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Decitabine (Primary) ; Venetoclax (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Sep 2021 Results (n=20) assessing the tolerability and efficacy of maintenance therapy with low-dose DEC (LDEC) plus VEN to prevent relapse after allo-HSCT for high-risk AML/MDS patients published in the Cancer Science
    • 01 Oct 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top